1,488 results on '"chronic venous disease"'
Search Results
2. The sonographic features of lymph node venous networks and flow patterns in patients with primary chronic venous disease.
- Author
-
Liu, Gaorui, Jillian Clarke, Yong Liu, Yunwei Zhang, and Mohan, Irwin
- Subjects
- *
LYMPH nodes , *LEG , *DOPPLER ultrasonography , *VEINS , *VARICOSE veins , *DESCRIPTIVE statistics , *CHRONIC diseases , *VENOUS insufficiency , *DISEASE relapse , *NEOVASCULARIZATION - Abstract
Background: Our study aims to enhance the understanding of lymph node venous networks (LNVNs) by summarising their anatomical, sonographic features, and reflux patterns. Method: We examined 241 legs from 141 patients with primary chronic venous disease (CVD) using duplex ultrasound. Results: The findings indicated variations in the shape, size, vascularity, and echogenicity of LNVN. The superficial inguinal lymph node with reflux appeared slightly larger, exhibiting higher velocities in the hilar artery. Regarding connections, venous flow within LNVN was predominantly drained through the saphenofemoral junction (SFJ), anterior accessory great saphenous vein (AAGSV), and great saphenous vein (GSV). A significant number of LNVNs were observed to be associated with anterolateral thigh tributaries. The study also identified valve cusps within LNVN. Conclusion: This study revealed a 12% prevalence of primary LNVN. Understanding the anatomical and haemodynamic features of LNVN informs treatment strategies and potentially helps prevent the recurrence of varicose veins. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Effects of lower limb muscle strengthening on interface pressure in older adults undergoing inelastic compression: Randomized controlled clinical trial.
- Author
-
Simões Da Matta, Eduardo, Mosti, Giovanni, da Silva Corralo, Vanessa, Policeno de Moura, Glauciano, Branco de Quadros, Luciano, and De Sá, Clodoaldo Antônio
- Subjects
- *
EXERCISE physiology , *LEG , *PRESSURE , *EXERCISE therapy , *RANDOMIZED controlled trials , *DESCRIPTIVE statistics , *FUNCTIONAL status , *MUSCLE strength , *PRE-tests & post-tests , *COMPRESSION therapy , *ANALYSIS of variance , *PHYSICAL mobility , *OLD age - Abstract
bjective: To analyze the effects of lower limb muscle strengthening on interface pressure (IP), static stiffness index (SSI), dynamic stiffness index (DSI), and walking pressure amplitude (WPA) in older adults undergoing inelastic compression therapy. Method: Forty-three healthy older adults of both sexes (Age: 66.2 ± 4.4 years) met the eligibility criteria and completed all stages of the study (Resistance Training -- RT: N = 20; Control -- CONT: N = 23). Body composition, strength and functional mobility of lower limbs, IP, SSI, DSI, and WPA were evaluated before and after intervention. Results: The two-way ANOVA with repeated measures demonstrated a significant time-group interaction effect on muscular strength for 1-RM [F (1, 41) = 21.091; p ≤ 0.001], IP in the orthostatic position [F (1, 41) = 5.124; p ≤ 0.05], minimum WPA [F (1, 41) = 10.999; p ≤ 0.05], maximum WPA [F (1, 41) = 8.315; p ≤ 0.05], DSI minimum (F (1, 41) = 4.608; p ≤ 0.05), DSI maximum (F (1, 41) = 8.926; p ≤ 0.05), and on the delta DSI (F (1, 41) = 7.891; p ≤ 0.05). Conclusions: In RT group, the increase in lower limb muscle strength was accompanied by an increase in IP in foot dorsiflexion and plantar flexion maneuvers, both in the standing position (DSI) and during gait (WPA). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Mobile ultrasound vascular assessment (MUVA) for remote and conflict areas
- Author
-
Moreno Rocha, Oscar Y., Pinto, Paula, Consuegra, Maria C., Cifuentes, Sebastian, and Ulloa, Jorge H.
- Published
- 2024
- Full Text
- View/download PDF
5. Sex/Gender Differences in Chronic Venous Disease
- Author
-
Han, Ahram and Kim, Nayoung, editor
- Published
- 2024
- Full Text
- View/download PDF
6. Investigation of the Pressure Transmission Characteristics of Miniaturised Air Bladders for Medical Compression Textiles
- Author
-
Hedigalla, D. P., Ehelagasthenna, M., Nandasiri, G. K., Nissanka, I. D., Amarasinghe, Y. W. R., Ghosh, Arindam, Series Editor, Chua, Daniel, Series Editor, de Souza, Flavio Leandro, Series Editor, Aktas, Oral Cenk, Series Editor, Han, Yafang, Series Editor, Gong, Jianghong, Series Editor, Jawaid, Mohammad, Series Editor, Gupta, Deepti, editor, Majumdar, Abhijit, editor, and Gupta, Sanjay, editor
- Published
- 2024
- Full Text
- View/download PDF
7. Chronic VEnous dIsorders maNagement and Treatment effectivenesS evaluaTion in Chronic vEnous Disease, an International Program (VEIN STEP)
- Published
- 2023
8. T.I.M.E.R.S. for foot ulcers – current management strategy
- Author
-
Artur Furga, Barbara Dalkowska, Jędrzej Dzięgielewski, and Iga Barczak
- Subjects
venous ulcers ,chronic venous disease ,compression ,hard-to-heal wounds ,Nursing ,RT1-120 - Abstract
Managing venous ulcers poses significant challenges for nursing personnel. This article outlines the current strategies employed in addressing venous ulcers, with particular emphasis on the updated T.I.M.E.R.S. wound assessment tool and compression therapy. Diagnosis should consider risk factors associated with chronic venous disease as well as other conditions such arterial ischaemia, ulcers related to diabetic neuropathy, or cancer. Doppler duplex ultrasound is typically conducted to validate the diagnosis. In the treatment of chronic wounds, implementing the updated wound assessment strategy T.I.M.E.R.S. is recommended. Optimal wound management requires tailored dressings and usage of antimicrobial agents. Application of local antibiotics on wounds should be avoided, with the exception of gentamicin embedded in a collagen matrix presented in the form of a sponge. Correctly adjusted com-pression therapy is a gold standard of treatment. Pentoxifylline is advised as an oral treatment to expedite the rate of ulcer healing.
- Published
- 2024
- Full Text
- View/download PDF
9. Key Regulators of Angiogenesis and Inflammation Are Dysregulated in Patients with Varicose Veins.
- Author
-
Zalewski, Daniel, Chmiel, Paulina, Kołodziej, Przemysław, Kocki, Marcin, Feldo, Marcin, Kocki, Janusz, and Bogucka-Kocka, Anna
- Subjects
- *
VARICOSE veins , *MONONUCLEAR leukocytes , *NEOVASCULARIZATION , *INFLAMMATION , *GENE expression - Abstract
Varicose veins (VVs) are the most common manifestation of chronic venous disease (CVD) and appear as abnormally enlarged and tortuous superficial veins. VVs result from functional abnormalities in the venous circulation of the lower extremities, such as venous hypertension, venous valve incompetence, and venous reflux. Previous studies indicate that enhanced angiogenesis and inflammation contribute to the progression and onset of VVs; however, dysregulations in signaling pathways associated with these processes in VVs patients are poorly understood. Therefore, in our study, we aimed to identify key regulators of angiogenesis and inflammation that are dysregulated in patients with VVs. Expression levels of 18 genes were analyzed in peripheral blood mononuclear cells (PBMC) using real-time PCR, as well as plasma levels of 6 proteins were investigated using ELISA. Higher levels of CCL5, PDGFA, VEGFC, TGF-alpha, TGF-beta 1, and VEGF-A, as well as lower levels of VEGFB and VEGF-C, were found to be statistically significant in the VV group compared to the control subjects without VVs. None of the analyzed factors was associated with the venous localization of the varicosities. The presented study identified dysregulations in key angiogenesis- and inflammation-related factors in PBMC and plasma from VVs patients, providing new insight into molecular mechanisms that could contribute to the development of VVs and point out promising candidates for circulatory biomarkers of this disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Acute phase determinant of post-thrombotic syndrome: A review of the literature.
- Author
-
Khider, Lina, Planquette, Benjamin, Smadja, David M., Sanchez, Olivier, Rial, Carla, Goudot, Guillaume, Messas, Emmanuel, Mirault, Tristan, and Gendron, Nicolas
- Subjects
- *
POSTTHROMBOTIC syndrome , *LITERATURE reviews , *LOW-molecular-weight heparin , *VENOUS thrombosis , *ANTICOAGULANTS , *THROMBOTIC thrombocytopenic purpura - Abstract
Post-thrombotic syndrome (PTS) is the main long-term complication of deep vein thrombosis (DVT). Several therapies are being evaluated to prevent or to treat PTS. Identifying the patients most likely to benefit from these therapies presents a significant challenge. The objective of this review was to identify risk factors for PTS during the acute phase of DVT. We searched the PubMed and Cochrane databases for studies published between January 2000 and January 2021, including randomized clinical trials, meta-analyses, systematic reviews and observational studies. Risk factors for PTS such as proximal location of DVT, obesity, chronic venous disease, history of DVT are associated with higher risk of PTS. On the initial ultrasound-Doppler, a high thrombotic burden appears to be a predictor of PTS. Among the evaluated biomarkers, some inflammatory markers such as ICAM-1, MMP-1 and MMP-8 appear to be associated with a higher risk of developing PTS. Coagulation disorders are not associated with risk of developing PTS. Role of endothelial biomarkers in predicting PTS has been poorly explored. Lastly, vitamin K antagonist was associated with a higher risk of developing PTS when compared to direct oral anticoagulants and low molecular weight heparin. Several risk factors during the acute phase of VTE are associated with an increased risk of developing PTS. There is a high-unmet medical need to identify potential biomarkers for early detection of patients at risk of developing PTS after VTE. Inflammatory and endothelial biomarkers should be explored in larger prospective studies to identify populations that could benefit from new therapies. • Post-thrombotic syndrome (PTS) is a long-term complication of deep vein thrombosis (DVT). • To date, the pathophysiology of PTS is poorly understood. • There is a high unmet need for the early identification of patients who will develop PTS. • Proximal DVT, obesity, previous venous insufficiency, history of DVT are associated with risk of PTS. • No routine biological markers are associated with risk of PTS. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. The Other Side of Chronic Venous Disorder: Gaining Insights from Patients' Questions and Perspectives.
- Author
-
Bissacco, Daniele and Pisani, Chiara
- Subjects
- *
PATIENTS' attitudes , *PATIENT compliance , *SAPHENOUS vein , *VARICOSE veins , *MEDICAL personnel , *SELF-efficacy - Abstract
Venous disorders encompass a diverse range of manifestations and diseases, impacting a significant portion of the population. While life-threatening conditions are uncommon in non-thrombotic disorders, like telangiectasias or uncomplicated varicose veins (VVs), these conditions still have a substantial impact on affected individuals. Ensuring that patients are well informed about their venous disorder is a crucial step in their treatment journey. Providing them with valuable information regarding the disease's natural progression and available therapeutic options plays a pivotal role in optimizing their care. When patients are diagnosed with venous disorders, they often have numerous questions and concerns they want to discuss with their healthcare providers. Addressing these inquiries not only improves patients' knowledge and understanding but also influences their treatment compliance and overall outcomes. Therefore, it is of utmost importance to provide comprehensive explanations that address any doubts, uncertainties, and areas of confusion that patients may have. This report aims to present a concise, practical, and informative guide to venous disorders, focusing specifically on the common questions frequently raised by patients in everyday clinical practice. By serving as a valuable resource for healthcare professionals working in the field of venous diseases, this guide equips them with the necessary tools to effectively address patients' concerns and provide optimal care. By bridging the gap between patients' inquiries and medical expertise, this guide strives to enhance therapeutic outcomes and improve the overall management of venous disorders, ultimately empowering patients in their treatment journey. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Prevalence, clinical presentation, and risk factors of chronic venous disease in Cameroon: A general population-based study.
- Author
-
Ngatchou, William, Barche, Blaise, Temgoua, Mazou, Metouguena, Serge Erwich, Jutcha, Ivan, Mvondo, Charles Mve, Kamdem, Félicité, Dzudie, Anastase, Ndjoh, Samuel, Johne, Marcel, Metogo, Junette, Ndom, Marie Solange, Sango, Joseph, Ngo Yon, Carole, Moulium, Sidick, Lade, Viche, Kuaté, Liliane Mfeukeu, Menanga, Alain Patrick, Sobngwi, Eugène, and Njock, Richard
- Subjects
- *
RISK assessment , *RESEARCH funding , *STATISTICAL sampling , *FISHER exact test , *SEX distribution , *VENOUS thrombosis , *HYPERTENSION , *SMOKING , *MULTIPLE regression analysis , *DISEASE prevalence , *FAMILY history (Medicine) , *CHI-squared test , *AGE distribution , *DESCRIPTIVE statistics , *MULTIVARIATE analysis , *CHRONIC diseases , *ODDS ratio , *VENOUS insufficiency , *SOCIODEMOGRAPHIC factors , *COMPARATIVE studies , *DATA analysis software , *CONFIDENCE intervals , *DIABETES , *OBESITY , *ECONOMIC aspects of diseases , *DISEASE risk factors , *SYMPTOMS - Abstract
Introduction: Chronic venous disease is a global public health problem, with high morbidity and economic distress. There is scarcity of data on this disease in sub-Saharan Africa. Methods: We conducted the first population-based study over a period of 20 months from 1st February 2020 to 30th September 2021 in the 10 regions of Cameroon. A stratify sampling method was chose to select study site. Socio-demographic data, personal and family history, anthropometric parameters, clinical signs, illustrative images, CEAP (Clinical-Etiological-Anatomical-Pathophysiological) classification revised in 2004, VCSS (venous Clinical Severity Score) and risk factor assessment score were used to construct the survey form. Chi-squared test and Fischer exact test were used to compare the prevalence of chronic venous disease across different potential risk factors (sex, age category, previous history of deep vein thrombosis, hypertension, diabetes, smoking status, obesity). Simple and multiple logistic regression models were used to obtain crude and adjusted odds ratio for risk factors associated with chronic venous insufficiency. Statistical analyses were done with R version 4.2 for Linux and the threshold for statistical significance was 0.05. Results: A total of 6578 participants were included in the study, with a mean age of 41.09 ± 16.02 years with female predominance (54.3%). The prevalence of chronic venous disease was 21.8% (95% CI: 20.8–22.9) and the prevalence of chronic venous insufficiency (C3–C6) was 7.02% (n = 462). Night cramps (43.2%), oedema (21.7%), lower limbs pain (20.4%) mostly worsens by walking and heavy legs (16.2%) were more common symptoms. The mean total venous clinical severity score was 0.69 ± 1.76 and this score had a significant positive correlation with C classification (p <.001). In the multivariate analysis, the following factors were independently associated with CVD: Male gender (aOR: 1.27; 95%CI: 1.04–1.56; p =.021), retired people (aOR: 46.9; 95% CI: 12.6–174.5; p <.001), hypertension (aOR: 289.5; 95%CI: 169.69–493.1; p <.001), diabetes (aOR: 2.19; 95% CI: 1.21–3.96; p =.009), obesity (aOR: 10.22; 95%CI: 7.67–13.62; p <.001). Smoking appears as a protective factor (aOR: 0.18; 95%CI: 0.10–0.30; p <.001). Conclusion: Chronic venous disease is frequent in Cameroon and main traditional cardiovascular risk factors are associated to this condition. Systematic screening of the CVD in these specific groups could reduce the burden of the disease and its economic impact. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Assessment of the Tolerance of Dobenox Forte ® in Patients with Chronic Venous Disease.
- Author
-
Chudek, Jerzy, Almgren-Rachtan, Agnieszka, Pastuszka, Agnieszka, and Ziaja, Damian
- Subjects
- *
CHRONICALLY ill , *ANKLE , *CALVES - Abstract
This prospective, observational, multicenter study assessed the tolerance of Dobenox Forte®, the first approved over-the-counter product containing calcium dobesilate, in 1795 outpatients with chronic venous disease (CVD) in daily clinical practice. In addition, the effectiveness (decrease in circumferences of a more affected limb at the ankle and middle part of the calf, and changes in the severity of CVD signs) was assessed. No adverse events related to use of the preparation were reported in a period of 64 ± 20 days. Dobenox Forte® use was associated with a reduction in calf circumference by 13.1 mm (95%CI: 12.2–14.1) and in ankle circumference by 9.7 mm (95%CI: 9.2–11.0) in patients reporting swelling of the lower legs (60.0% of the cohort). A reduction in calf and ankle circumference by at least 1 cm was achieved in 34.9% and 24.9% of patients, respectively. The percentages of patients reporting moderate to very severe lower limb heaviness decreased from 96.6% to 56.0%, calf cramps decreased from 91.0% to 41.0%, calf pain decreased from 89.2% to 43.7%, swelling decreased from 86.1% to 38.8%, and burning sensation that worsens when standing decreased from 79.0% to 33.7%. The medicinal product Dobenox Forte® is well tolerated by patients and seems to effectively reduce the symptoms of CVD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Factores de riesgo cardiovascular y su relación con la progresión de la enfermedad venosa crónica.
- Author
-
Padilla-Hernández, Leopoldo E., Hernández-Hurtado, Omar A., Flores-Ramírez, Carlos, Santoscoy-Ibarra, Joaquín M., Enríquez-Sánchez, Luis B., Hinojos-Flote, Raúl A., Delgado-Ortega, Dalia G., and Carrasco-Arredondo, Yarazi M.
- Abstract
Copyright of Revista Mexicana de Angiología is the property of Publicidad Permanyer SLU and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
15. Clinical evidence and rationale of mesoglycan to treat chronic venous disease and hemorrhoidal disease: a narrative review.
- Author
-
Gallo, Gaetano, Picciariello, Arcangelo, Tufano, Antonella, and Camporese, Giuseppe
- Abstract
Chronic venous disease (CVD) and hemorrhoidal disease (HD) are among the most common vascular diseases in the world, with CVD affecting 22–41% of the population in Europe and HD having a point prevalence of 11–39%. The burden is substantial in terms of the effect of symptoms on patients' health-related quality of life (HRQoL) and direct/indirect medical costs. Treatment begins with lifestyle changes, compression in CVD and topical therapies in HD, and escalates as needed through oral therapies first and eventually to surgery for severe disease. CVD and HD share etiological features and pathological changes affecting the structure and function of the tissue extracellular matrix. Mesoglycan, a natural glycosaminoglycan (GAG) preparation composed primarily of heparan sulfate and dermatan sulfate, has been demonstrated to positively impact the underlying causes of CVD and HD, regenerating the glycocalyx and restoring endothelial function, in addition to having antithrombotic, profibrinolytic, anti-inflammatory, antiedema and wound-healing effects. In clinical trials, oral mesoglycan reduced the severity of CVD signs and symptoms, improved HRQoL, and accelerated ulcer healing. In patients with HD, mesoglycan significantly reduced the severity of signs and symptoms and the risk of rectal bleeding. In patients undergoing excisional hemorrhoidectomy, adding mesoglycan to standard postoperative care reduced pain, improved HRQoL, reduced incidence of thrombosis, and facilitated an earlier return to normal activities/work, compared with standard postoperative care alone. The clinical effects of mesoglycan in patients with CVD or HD are consistent with the agent's known mechanisms of action. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Can physical exercise improve venous function in the context of chronic venous diseases? The impact of sport on varicose veins of the lower limbs - a review
- Author
-
Adam Salwa, Natalia Gajdzińska, Weronika Rostkowska, Wojciech Rutkowski, Maciej Rzepka, Karolina Sztuba, Justyna Puchała, Katarzyna Rymaszewska, Dominika Starzomska, and Karolina Basiura
- Subjects
Physical Activity ,chronic venous disease ,venous insufficiency ,hypertension ,Obesity ,Sports Activities ,Sports ,GV557-1198.995 ,Sports medicine ,RC1200-1245 - Abstract
Introduction: Varicose veins, a common form of chronic venous disease, arise from the dysfunction of veins in the lower limbs due to increased pressure and impaired blood flow. Regular physical activity and a balanced diet are crucial in managing and potentially improving symptoms of this condition. Material and methods: We have gathered the available materials and scientific reports, analyzing and summarizing them in a single study. Aim of study: We aimed to evaluate how physical activity and lifestyle changes impact the progression and management of varicose veins and chronic venous disease. Conclusion: The study underscores the significant role of physical activity and lifestyle changes in managing varicose veins and chronic venous disease. By enhancing calf muscle function and improving venous blood flow, these interventions can help reduce symptoms, prevent disease progression, and potentially decrease the need for surgical treatments.
- Published
- 2024
- Full Text
- View/download PDF
17. Treatment of varicose veins using the Cryo laser after foam technique
- Author
-
Marcos M. Fonseca, MD, Faberson J. Mocelin, MD, Lara R. Poltronieri, MD, and Jose L. Guimaraes Filho, MD
- Subjects
Chronic venous disease ,Leg veins ,Sclerotherapy ,Varicose veins ,Surgery ,RD1-811 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Sclerotherapy is the treatment of choice for telangiectasias and reticular veins. The most common side effects of this procedure are hyperpigmentation and matting, which are feared owing to their aesthetic damage and difficulty of treatment. Combined treatments with laser and hypertonic glucose sclerotherapy have been described with excellent results, but limited to treatment of veins of ≤2 mm in diameter. Cryo laser after foam sclerotherapy is a procedure to treat reticular veins in the lower extremities that utilizes first foam sclerotherapy with polidocanol than immediately followed by transdermal Nd:YAG 1064 laser treatment and we can treat veins ≤5 mm. This report presents a successful case of varicose vein treatment using combined transdermal laser and sclerotherapy with foam sclerotherapy with polidocanol to treat veins >2.5 mm in diameter.
- Published
- 2024
- Full Text
- View/download PDF
18. Varicose Veins and the Diagnosis of Chronic Venous Disease in the Lower Extremities
- Author
-
Jae Ho Chung and Seonyeong Heo
- Subjects
chronic venous disease ,varicose veins ,lower extremity ,diagnosis ,ultrasonography ,Medicine (General) ,R5-920 - Abstract
Varicose veins usually present in the superficial veins of the lower extremities and are one of the main clinical presentations of chronic venous disease (CVD). Patients’ symptoms may vary according to the pathophysiology, location, and severity of CVD. The prevalence of CVD in Korea has been increasing gradually. However, due to its broad clinical spectrum and the subjective nature of its diagnosis using ultrasound, discrepancies in diagnostic and treatment quality may exist among treating physicians. There have been recent efforts to improve the quality of the diagnosis and treatment of varicose veins in Korea by standardizing the diagnostic criteria and the indications for treatment. This study is a comprehensive review of the clinical manifestations and diagnostic criteria of CVD based on the most recent international and domestic guidelines and reports.
- Published
- 2024
- Full Text
- View/download PDF
19. Efficacy of High-Dose Diosmin Therapy in Chronic Venous Disease Treated with Endovenous Ablation: A Quality-of-Life Analysis
- Author
-
Antonia Rinaldi, Rita Zeno, Antonio Peluso, Luca del Guercio, Maurizio Sodo, Davide Turchino, Ruggero Iandoli, Davide Costa, Raffaele Serra, and Umberto Marcello Bracale
- Subjects
venoactive drugs ,chronic venous disease ,quality-of-life ,venous symptoms ,endovenous ablation ,mechanochemical ablation ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background. Vasoactive drugs are considered an important therapeutic tool in managing phlebolymphologic disease. The current study was performed to evaluate the results of a high-dose diosmin-based combination (Venoplant 2g) in symptomatic patients with chronic venous disease (CVD), treated with endovascular venous surgery, regarding the efficacy of this treatment and the clinical signs and patients’ compliance. Methods: We identified, between April 2022 and March 2023, 50 patients with symptomatic CVD who underwent endovenous ablation and additionally were administered high-dose micronized diosmin. Parameters analyzed in the pre- and post-operative period were the venous clinical severity score (VCSS), the calf circumference, and a VEINES-QOL/Sym questionnaire. Treatment efficacy was assessed in post-operative follow-ups at 1 month and 2 months. Results: Quality-of-life analysis showed a significant improvement between t1 and t2 in both tests administered (VEINES-QOL/Sym: 55.2 ± 2.9, 39.2 ± 12.3, p: 0.001) (VCSS: 6.6 ± 1, 5.1 ± 0.7, p: 0.001). At the secondary endpoint, the results maintained the same improvement trend. Calf circumference was significantly reduced between t1 and t3 (41.7 ± 5.1, 38.3 ± 3.4, p: 0.001). Conclusion: High-dose diosmin, combined with sweet clover 320 mg, Centella asiatica 40 mg, and Vitamin C 200 mg, in patients treated with endovenous ablation, can be significantly effective in terms of clinical results in treating superficial venous disease. A patient’s calf circumference was also found to have decreased considerably during follow-up. No adverse effects have been recorded to date.
- Published
- 2024
- Full Text
- View/download PDF
20. Vein wall thickness and severity of pulmonary involvement due to sars n-cov2 virus infection
- Author
-
Gennaro Quarto, Giacomo Benassai, Annamaria Colao, Antonio Cittadini, Paolo Antonio Ascierto, Rosario Pivonello, Andrea Elefante, Marialuisa Bocchino, Alberto Maria Marra, Ivan Gentile, Gianluca Benassai, Andrea Miletti, Francesca Calemma, Ermenegildo Furino, and the members of FACTA study group
- Subjects
COVID-19 ,Vein wall thickness ,ARDS ,Chronic venous insufficiency ,Chronic venous disease ,Medicine - Abstract
Abstract Background An observational study involving patients recovered from COVID-19 was conducted in order to evaluate the presence/absence of vein wall thickness increasing, according to the severity of pulmonary involvement quantified with a CT-scoring system. Methods The venous wall thickness (VWT) of 31 patients (23 males and 8 females) with COVID 19 previously admitted to Federico II University Hospital of Naples was evaluated through ultrasound measurement of the common femoral Vein 1 cm proximal to the saphenous-femoral junction and the popliteal Vein 1 cm distal to the confluence of gemellary veins. Measurements were taken with an automated tool to avoid human error. All patients were evaluated in the supine position. Patients were then stratified into two groups, VWT > 1 mm and VWT 1 mm group was 7.4 (S.D. 4.83), whilst the mean value of the COVID score in the VWT
- Published
- 2024
- Full Text
- View/download PDF
21. Sulodexide in the Treatment of Chronic Primary Venous Disease of the Lower Extremities (SuloPrima)
- Author
-
Alfasigma S.p.A.
- Published
- 2023
22. Acinetobacter pittii thrombophlebitis complicating cyanoacrylate closure procedure
- Author
-
Javier J. Barranco-Trabi, MD, Kaushal Desai, MD, Daniel Chen, MD, Dwight Kellicut, MD, Wiberg Brandon, DO, Sharon Chi, DO, Nathanial K. Copeland, MD, Edwin Kamau, PhD, and Viseth Ngauy, MD
- Subjects
Acinetobacter pittii ,Chronic venous disease ,Cyanoacrylate closure procedure ,Surgery ,RD1-811 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Chronic venous disease is a common condition causing pain, discomfort, and skin changes that effect quality of life and productivity. Various treatment modalities have been developed to manage retrograde venous blood flow and its associated complications, ranging from conservative therapy to more invasive techniques such as endothermal ablation and cyanoacrylate closure (CAC). Recently, CAC has gained popularity due to its faster recovery time and lower incidence of postprocedure discomfort and complications. The most commonly reported side effects include phlebitis, access site bruising or pain, and dermatitis. We present a case of phlebitis caused by Acinetobacter pittii following a CAC procedure using the VenaSeal device (Medtronic) in a patient with diabetes. The patient required surgical resection of the affected vein and prolonged antibiotic therapy. Bacterial contamination of the cyanoacrylate adhesive within a vein poses a significant treatment challenge with antibiotics alone due to biofilm production. Aggressive source control with removal of the adhesive-treated vein could be required for treatment of endovascular infections resulting from these common procedures.
- Published
- 2024
- Full Text
- View/download PDF
23. Can plethysmography have a greater place in the diagnosis, treatment and follow-up of chronic venous insufficiency?
- Author
-
Taner, Temmuz and Güven, Hakan
- Subjects
- *
PLETHYSMOGRAPHY , *CHRONIC diseases , *DISEASE prevalence , *SOCIOECONOMICS , *ULTRASONIC imaging - Abstract
Objectives: Chronic venous insufficiency (CVI) is one of the most common venous diseases. CVI is an important clinical picture with a high prevalence, low quality of life, and high diagnosis and treatment costs. Therefore, diagnosis, follow-up, and treatment are important for the patient's socioeconomic and life quality. In this study, we aimed to better examine a test used in the diagnosis, treatment, and follow-up of CVI. Methods: In this retrospective study, 683 patients diagnosed with CVI, who had endovenous laser ablation (EVLA) indications were evaluated between June 2013 and November 2018. EVLA procedure performed on all patients. Preoperative, postoperative 1st and 6th month Doppler USG (ultrasonography), plethysmography, and VCSS (Venous Clinical Severity Score) questionnaire was made to all patients. Results: As a result of our study, we found that there was a significant difference between the preoperative plethysmography and VCSS results of the patients and the postoperative 1st and 6th month results. With the significant difference in the VCSS questionnaire, we have shown that plethysmography gives accurate results in the diagnosis and treatment of CVI since it is an individual, quantitative, and easy test. Conclusions: EVLA is an effective and safe method in patients with venous insufficiency. Since Doppler USG is person and device dependent, we think that plethysmography, which can be used in every clinical setting and provides quantitative results independent of the person, can be used more frequently in the diagnosis and treatment of venous insufficiency. In addition, we think that plethysmography can be used as a valuable additional method in the diagnosis and follow-up of such patients, due to the venous hemodynamic data that Doppler USG cannot provide. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Sclerotherapy: Indications and safety volumes.
- Author
-
Tan, Matthew, Moreno, Hernan Bauza, Bechter-Hugl, Beate, Gianesini, Sergio, Connor, David, Parsi, Kurosh, and Davies, Alun H
- Subjects
- *
CHRONIC disease treatment , *VEINS , *ULTRASONIC imaging , *MEDICAL protocols , *SCLEROTHERAPY , *VARICOSE veins , *VASCULAR diseases , *PATIENT safety , *DISEASE management , *THERAPEUTICS - Abstract
The article discusses the indications and safe volumes for sclerotherapy in the treatment of chronic venous disease, emphasizing the need for careful patient selection and tailored treatment approaches. Topics include contraindications for sclerotherapy, diagnostic evaluation using duplex ultrasound, and recommendations for sclerosant type and concentration based on target vessel characteristics.
- Published
- 2024
- Full Text
- View/download PDF
25. Vein wall thickness and severity of pulmonary involvement due to sars n-cov2 virus infection.
- Author
-
Quarto, Gennaro, Benassai, Giacomo, Colao, Annamaria, Cittadini, Antonio, Ascierto, Paolo Antonio, Pivonello, Rosario, Elefante, Andrea, Bocchino, Marialuisa, Marra, Alberto Maria, Gentile, Ivan, Benassai, Gianluca, Miletti, Andrea, Calemma, Francesca, Furino, Ermenegildo, Angelis, Cristina, Menafra, Davide, Garifalos, Francesco, De Palma, Giovanni Domenico, Annunziata, Maria Carmela, and Cantelli, Maria Teresa
- Subjects
- *
VIRUS diseases , *SARS-CoV-2 , *COVID-19 , *FEMORAL vein , *VEINS - Abstract
Background: An observational study involving patients recovered from COVID-19 was conducted in order to evaluate the presence/absence of vein wall thickness increasing, according to the severity of pulmonary involvement quantified with a CT-scoring system. Methods: The venous wall thickness (VWT) of 31 patients (23 males and 8 females) with COVID 19 previously admitted to Federico II University Hospital of Naples was evaluated through ultrasound measurement of the common femoral Vein 1 cm proximal to the saphenous-femoral junction and the popliteal Vein 1 cm distal to the confluence of gemellary veins. Measurements were taken with an automated tool to avoid human error. All patients were evaluated in the supine position. Patients were then stratified into two groups, VWT > 1 mm and VWT < 1 mm. Lung damage was assessed through thoracic High Resolution Computer Tomography and subsequently quantified using the scoring system set out by Chung et al. CEAP-C class was calculated for all patients. Results: The mean value of COVID score in VWT > 1 mm group was 7.4 (S.D. 4.83), whilst the mean value of the COVID score in the VWT < 1 mm group was 3.82 (S.D 3.34). These findings were determined to be statistically significant in a two-tie Student-T test. The linear regression test between VWT and Covid score values demonstrated a direct relationship between the two variables. Conclusion: These results demonstrate a link between two different aspects of the pathological effects on the vessels during a SARS-COV 2 infection. As such a common primum movens can be hypothesized in both micro-thrombotic and inflammatory processes relating to COVID 19. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Safety and Efficacy of Combining Saphenous Endovenous Laser Ablation and Varicose Veins Foam Sclerotherapy: An Analysis on 5500 Procedures in Patients With Advance Chronic Venous Disease (C3-C6).
- Author
-
Baraldi, Christian and Bissacco, Daniele
- Subjects
- *
CHRONIC disease treatment , *SAPHENOUS vein , *ULTRASONIC imaging , *VENOUS insufficiency , *LASER therapy , *MEDICAL care , *PARESTHESIA , *TREATMENT effectiveness , *VENOUS thrombosis , *VARICOSE veins , *SCLEROTHERAPY , *DESCRIPTIVE statistics , *COMBINED modality therapy , *ECCHYMOSIS , *ADVERSE health care events , *PATIENT safety , *EVALUATION , *DISEASE complications - Abstract
Background: endovenous laser ablation (EVLA) represents the gold standard in treating both great and small saphenous veins (GSV and SSV) incompetence. To achieve a "no-scalpel" procedure in patients with chronic venous insufficiency (CVI, CEAP C3-C6), concomitant phlebectomies could be replaced by ultrasound-guided foam sclerotherapy (UGFS) into varicose tributaries. The aim of this study is to present a single-centre experience on EVLA + UGFS for patients with CVI secondary to varicose veins and saphenous trunk incompetence, analysing ling-term outcomes. Methods: all consecutive patients with CVI and treated by EVLA + UGFS from 2010 to 2022 were included in the analysis. EVLA was performed using a 1470-nm diode laser (LASEmaR® 1500, Eufoton, Trieste, Italy), adapting the linear endovenous energy density (LEED) depending on saphenous trunk diameter. Tessari method was used for UGFS. Patients were evaluated clinically and by duplex scanning at 1, 3 and 6 months, and annually up to 4 years, to assess treatment efficacy and adverse reactions. Results: 5500 procedures in 4895 patients (3818 women, 1077 men) with a mean age of 51.4 years were analysed during the study period. A total of 3950 GSVs and 1550 SSVs were treated with EVLA + UGFS (C3 59%, C4 23%, C5 17% and C6 1%). Neither deep vein thrombosis nor pulmonary embolism were detected during follow-up, as well as superficial burns. Ecchymoses (7%), transitory paraesthesia (2%), palpable vein induration/superficial vein thrombosis (15%) and transient dyschromia (1%) were registered. Saphenous and tributaries closure rate at 30 days, 1 and 4 years were 99.1%, 98.3% and 97.9%, respectively. Conclusions: EVLA + UGFS for an extremely minimally invasive procedure appears to be a safe technique, with only minor effects and acceptable long-term outcomes, in patients with CVI. Further prospective randomized studies are needed to confirm the role of this combined therapy in such patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Stasis Dermatitis: Pathophysiology, Current Treatment Paradigms, and the Use of the Flavonoid Diosmin.
- Author
-
AWAD, NARDIN, HETZEL, JOHN D., BHUPALAM, VISHNU, and NESTOR, MARK S.
- Subjects
- *
FLAVONOIDS , *PATHOLOGICAL physiology , *SKIN inflammation , *HEALING , *TREATMENT effectiveness , *ROSACEA - Abstract
OBJECTIVE: We sought to examine the role of flavonoids, particularly diosmin, as a therapeutic agent for stasis dermatitis (SD) through discussion of pathophysiology, current treatment paradigms, potential mechanisms of action, and a systematic review of evidence on clinical efficacy. METHODS: In addition to articles on pathophysiology and standard treatment, a search of PubMed was conducted using the following query: ("Diosmin" OR "MPFF" OR "Micronized Purified Flavonoid Fraction" OR "Flavonoid") AND ("Stasis Dermatitis" OR "Venous Ulcer" OR "Lipodermatosclerosis"). Emphasis was placed on studies that were randomized controlled trials examining an oral flavonoid against a placebo or standard of care. RESULTS: Diosmin is effective at improving stasis changes, increasing ulcer healing frequency, decreasing the time to ulcer healing, and reducing tissue edema. They also cause significant improvement in patient quality of life and reduction of venous symptoms. Diosmin has been shown to have a favorable safety profile with very few mild adverse events which did not differ significantly from placebo. Flavonoids also appear to be effective for other dermatologic conditions, including rosacea and senile purpura. CONCLUSION: There is a growing body of evidence indicating that diosmin has therapeutic efficacy in managing stasis dermatitis. Data from studies in diseases with pathogenic similarities suggests the potential for even broader dermatologic applications. [ABSTRACT FROM AUTHOR]
- Published
- 2024
28. Sex and the veins. A cross-sectional analysis on sexual dysfunction in patients with Chronic Venous Disease
- Author
-
Davide Costa, Nicola Ielapi, Umberto Marcello Bracale, Antonio Peluso, Roberto Minici, Michele Andreucci, and Raffaele Serra
- Subjects
Sexual dysfunction ,Chronic venous disease ,Quality of life ,ASEX ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Background: This study aimed to investigate the presence of sexual dysfunction (SD) in patients with Chronic Venous Disease (CVD) and if CVD treatments may have an impact on SD evolution in these patients. Methods: Inclusion criteria were patients of both sexes and genders, with minimum age of 18, with first diagnosis of CVD. Exclusion criteria were presence of known sexual dysfunction of organic origin, arterial system diseases, malignancies and endocrine system diseases. Included patients were administered the ASEX (Arizona Sexual Experience) questionnaire that was administered at the moment of study inclusion (T0), and for patients that resulted affected from sexual dysfunction, were administered also, after CVD treatments at 6 months (T1) and after 12 months (T2). Results: A total of 649 patients with CVD were recruited. After the administration of the ASEX questionnaire, 122 patients (18.8 %) resulted affected from SD. Female sex, C3–C6 clinical stages, and the presence of Coronary Artery Disease (CAD), hypertension, and hyperlipidemia were more associated with the presence of SD. SD improved in all patients’ population, especially after CVD treatment at T2. Conclusions: CVD patients may experience SD, especially in female sex, in more advanced disease stages. SD in CVD patients appears to improve after adequate CVD treatment.
- Published
- 2024
- Full Text
- View/download PDF
29. Evaluation of the Efficacy and Tolerability of Detralex in Patients With Chronic Venous Edema in Real Clinical Practice (VAP-PRO-C3)
- Published
- 2023
30. Management of bleeding varicose veins.
- Author
-
Tan, Matthew, Campbell, Bruce, Parsi, Kurosh, and Davies, Alun H
- Subjects
- *
HEMORRHAGE risk factors , *HEMORRHAGE treatment , *HEMORRHAGE prevention , *MEDICAL protocols , *RISK assessment , *PATIENT education , *FIRST aid in illness & injury , *COMPRESSION bandages , *INTERNATIONAL agencies , *VARICOSE veins , *SCLEROTHERAPY , *LIFE support systems in critical care , *COMPRESSION therapy , *DISEASE relapse , *HEMORRHAGE , *DISEASE complications ,MORTALITY risk factors - Abstract
The article focuses on the management of bleeding varicose veins, highlighting the potential risks and urgent need for medical attention. Topics discussed include first aid measures for patients experiencing bleeding, immediate clinical management in healthcare facilities, and the importance of timely referral to vascular specialists to prevent recurrence and ensure patient safety.
- Published
- 2024
- Full Text
- View/download PDF
31. Evaluation of the AIVARIX in Detecting Signs C 1-2 Classes of CVD (AIVARIX)
- Published
- 2022
32. A new compression stocking with well-defined pressure—a randomized controlled pilot study.
- Author
-
Källman, Ulrika, Fallenius, Melina, and Bååth, Carina
- Subjects
- *
EDEMA prevention , *PILOT projects , *HUMAN comfort , *COMPRESSION garments , *PRESSURE , *TREATMENT effectiveness , *RANDOMIZED controlled trials , *COMPARATIVE studies , *DESCRIPTIVE statistics , *RESEARCH funding , *STATISTICAL sampling , *DIFFUSION of innovations - Abstract
Background: To evaluate an innovative class I compression stocking with predetermined uniform pressure in comparison to a graduated class III compression stocking system, regarding edema reduction, interface pressure, and patient comfort. Method: Twenty-five patients with chronic venous disease, were randomized: 12 to investigational stocking, 13 to comparator stocking. Data collected at baseline and after 14 days. Results: Edema was significantly equal reduced to follow-up; mean −129.0 cm3 (SD 105; p =.004, Class I) and −223.7 cm3 (SD 120; p =.002, Class III), respectively. The investigational stocking lost significantly less compression pressure than the comparator stocking (p ≤.013). Participants in both groups perceived significant improvement regarding leg heaviness, leg swelling, and feelings of tightness and tingling (p ≤.016). Conclusion: The innovative investigational class I stocking appears to offer similar edema reduction and benefits to the comparator class III stocking. However, a larger and prolonged study is required. The study was registered in the ISRCTN-registry, ISRCTN17356077, https://www.isrctn.com/ISRCTN17356077. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. Cardiovascular Insights for the Appropriate Management of Chronic Venous Disease: A Narrative Review of Implications for the Use of Venoactive Drugs.
- Author
-
Gianesini, Sergio, De Luca, Leonardo, Feodor, Toni, Taha, Wassila, Bozkurt, Kursat, and Lurie, Fedor
- Abstract
Evidence suggests that chronic venous disease (CVD) may be a cardiovascular disorder, as patients with CVD are prone to developing arterial (atherosclerosis) and venous (thromboembolism) diseases. This may be partly explained by shared risk factors. Thus, patients with CVD or cardiovascular disease require careful history-taking and physical assessment to identify coexisting pathologies and risk factors. This article summarises a symposium at the XIX World Congress of the International Union of Phlebology held in Istanbul, Turkey, in September 2022. Common pathophysiological features of CVD and cardiovascular disease are endothelial injury, hypercoagulability and systemic inflammation. In CVD, inflammation primarily affects the microcirculation, with changes in capillary permeability, vein wall and valve remodelling and increase in oxidative stress. Once patients develop symptoms/signs of CVD, they tend to reduce their physical activity, which may contribute to increased risk of cardiovascular disease. Data show that the presence of CVD is associated with an increased risk of cardiovascular disease, including peripheral arterial disease and heart failure (HF), and the risk of adverse cardiovascular events increases with CVD severity. In addition, patients with cardiovascular disease, particularly those with HF, are at increased risk of venous thromboembolism (VTE) and should be assessed for VTE risk if they are hospitalised with cardiovascular disease. Therefore, CVD management must include a multi-specialty approach to assess risk factors associated with both the venous and arterial systems. Ideally, treatment should focus on the resolution of endothelial inflammation to control both CVD and cardiovascular disease. International guidelines recommend various conservative treatments, including venoactive drugs (VADs), to improve the symptoms/signs of CVD. Micronized purified flavonoid fraction (MPFF) is a VAD, with high-quality evidence supporting its use in relieving symptoms/signs of CVD and improving quality of life. Moreover, in large-scale observational studies, MPFF has shown superior effectiveness in real-world populations compared with other VADs. 3qqUjcBFSDSz8_qvuiGNf1 Video Abstract. (MP4 97173 kb) Plain Language Summary: Blood vessel disease can affect both arteries and veins; when it affects arteries, it is called cardiovascular disease, and when it affects veins, it is called chronic venous disease (CVD). In most cases, the underlying disease process is similar, irrespective of the type of blood vessels affected, and the risk of both CVD and cardiovascular disease is increased by age, smoking, overweight/obesity and diabetes. If cardiovascular disease affects arteries in the legs, the symptoms can be similar to that of CVD, with pain, feelings of leg heaviness or tiredness and skin changes. CVD and cardiovascular disease are usually treated by different specialists. A symposium was held at the XIX World Congress of the International Union of Phlebology in Istanbul, Turkey, in September 2022, to raise awareness of the relationship between the two conditions. The speakers described the common disease processes in CVD and cardiovascular disease, and how patients with CVD are at increased risk of cardiovascular disease, and vice versa. They reiterated the importance of thoroughly assessing patients with either cardiovascular disease or CVD to see if both arterial and venous disease were present. When patients have CVD, international treatment guidelines recommend various conservative treatments, including venoactive drugs, to improve symptoms and signs. There is high-quality evidence to support the use of the venoactive drug, micronized purified flavonoid fraction (MPFF), to improve quality of life and relieve a broad range of CVD symptoms/signs. Large-scale observational studies support the effectiveness of MPFF in a real-world population of patients with CVD compared with other venoactive drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. Moderní terapie chronického žilního onemocnění - co je nového?
- Author
-
Vlachovský, Robert and Novák, Jan
- Abstract
Copyright of Medicina Pro Praxi is the property of SOLEN sro and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
35. What is the prevalence of chronic venous disease among health care workers? A scoping review.
- Author
-
Benn, Sarah, Moore, Zena, Patton, Declan, O'Connor, Tom, Nugent, Linda, Harkin, Denis, and Avsar, Pinar
- Subjects
CHRONIC diseases ,SYSTEMATIC reviews ,MEDICAL personnel ,VENOUS insufficiency ,PSYCHOSOCIAL factors ,DISEASE prevalence ,DESCRIPTIVE statistics ,VARICOSE veins ,LITERATURE reviews - Abstract
Chronic venous disease (CVD) occurs because of structural or functional disturbances to the venous system of the lower limbs. Signs and symptoms include leg pain, swelling, varicose veins, and skin changes, with venous ulceration ultimately occurring in severe disease. To assess the prevalence of CVD among health care workers, a scoping review of existing publications exploring the prevalence of CVD among health care workers was conducted in July 2022. The Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines were used. A total of 15 papers met the inclusion criteria and these formed the basis of the review. Among health care workers, the mean prevalence of CVD was 58.5% and the mean prevalence for varicose veins was 22.1%. There is an increased prevalence of CVD in health care workers when compared with the general population. Therefore, there is a need for early diagnosis and the use of preventative measures to protect health care workers from CVD and varicose vein development. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
36. Xioglican Cream in Italian Patients with Chronic Venous Disease: A Post-Marketing Study Investigating Effects on Clinical and Cutaneous Signs and Symptoms.
- Author
-
Muratori, Ida Maria, Contorno, Francesco, and Amato, Corrado
- Abstract
Introduction: The progression of chronic venous disease (CVD) is characterized by edema of the legs and/or venous ulcers of the lower limbs in association with cutaneous signs and/or skin alterations, such as hyperpigmentation, corona phlebectatica, telangiectasia, eczematous dermatitis, lipodermatosclerosis, atrophie blanche, cellulitis, and induration. Xioglican cream is a galactosaminoglycan polysulfate and hyaluronic acid-containing medical device with strong hydrophilic, moisturizing, and soothing properties. This post-marketing observational study evaluated topical Xioglican cream in the amelioration of skin manifestations and clinical signs and symptoms in patients with CVD treated in routine clinical practice. Methods: Adult patients (18–75 years) with a clinical diagnosis of C2–C3 CVD according to Clinical, Etiology, Anatomy, and Pathophysiology (CEAP) classification who received 12 weeks of treatment with Xioglican (applied up to 3 times daily), according to investigator decision (and consistent with conventional clinical practice and established standard of care), were enrolled from two study sites in Italy. A range of endpoints were used to evaluate efficacy, safety, effect on patient quality of life (QoL), and patient satisfaction with topical application of Xioglican cream in the physiological restoration of skin signs and symptoms. Results: In patients with CVD (n = 30), Xioglican cream reduced CVD-related skin manifestations and associated symptoms, with significant reductions in leg circumference [mean ± standard deviation (SD): − 3.21 ± 3.39 cm for left and − 2.92 ± 2.70 cm for right legs, both p < 0.0001] and local edema (− 5.52 ± 7.94 cm, p = 0.0034) and significant improvement in Venous Clinical Severity Scores (mean 0.52 ± 1.94 decrease from baseline, p = 0.1952) observed after 12 weeks. Skin burning, pain, aching or tiredness, and QoL were also significantly improved. There was no change in CEAP classification. Globally, 92.0% of patients were "Very satisfied" or "Satisfied" with the product. Conclusions: Topical treatment with Xioglican cream improves the signs, symptoms, and QoL of patients with CVD class C2–C3. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
37. VEIN STEP: A Prospective, Observational, International Study to Assess Effectiveness of Conservative Treatments in Chronic Venous Disease.
- Author
-
Mezalek, Zoubida Tazi, Feodor, Toni, Chernukha, Larisa, Chen, Zhong, Rueda, Ana, Sánchez, Ignacio Escotto, Ochoa, Alejandro José González, Chirol, Joanna, Blanc-Guillemaud, Vanessa, Lohier-Durel, Caroline, and Ulloa, Jorge Hernando
- Abstract
Introduction: VEIN STEP was conducted to collect international data on the management of chronic venous disease (CVD) and to assess the effectiveness of conservative treatments for the relief of CVD signs and symptoms. Methods: This international, observational, prospective, longitudinal, cohort study recruited adult outpatients consulting for symptomatic CVD. The primary objective was the effectiveness of conservative treatments on symptoms, signs and quality of life in a real-life setting assessed using a range of patient-reported outcome measures: 10-cm Visual Analog and Patient Global Impression of Change scales for symptoms; Venous Clinical Severity Score for physician assessment of signs; and 14-item ChronIc Venous Insufficiency Questionnaire (CIVIQ-14) for quality of life. At inclusion, patients were prescribed conservative treatment according to the physicians' usual practice. Follow-up visits took place at weeks 2 and 4, with an optional week 8 visit. Results: The analysis set comprised 6084 subjects (78% female) from nine countries with a mean age of 50.6 ± 13.8 years and BMI of 28.0 ± 4.9 kg/m
2 . The most common CEAP classifications were C1 (23.0%), C2 (31.6%), and C3 (30.7%). Conservative therapy consisted of oral venoactive drugs (VADs; 95.8% of subjects) including micronized purified flavonoid fraction (MPFF 75.5%) and diosmin (18.8%), compression (52.0%), and topicals (31.5%). Conservative therapy led to global symptom improvement in 89% of patients after 2 weeks and 96% at 4 weeks. Pain, leg heaviness, cramps, and sensation of swelling were improved in 82%, 71%, 45.5%, and 46% of patients, respectively. Conservative therapy was associated with a decrease over time in patient-assessed global symptom intensity: – 2.37 ± 1.73 (P < 0.001) and physician-assessed disease severity – 1.83 ± 2.82 (P < 0.001). Among the VADs, MPFF-based conservative therapy was associated with the greatest reduction in symptom and sign intensity. Improvements in CIVIQ-14 were observed with all treatments but were greatest for MPFF. Conclusion: In this prospective study conducted in the real-world setting, treatment with conservative therapy, in particular MPFF, was associated with meaningful improvements in the clinical signs and symptoms of disease as well as in quality of life in patients with CVD. Trial Registration: ClinicalTrials.gov identifier NCT04574375. Plain Language Summary: Study Aim: The VEIN STEP study aimed to gather global data on managing chronic venous disease (CVD) and evaluate the usefulness of conservative (non-surgical) treatments for improving CVD signs and symptoms. Methods: Persons included in the study group had symptomatic CVD and were visiting outpatient clinics. The main aim was to measure how well treatments improved symptoms, physical signs of the illness, and quality of life. Different methods were used to measure these aspects, such as rating symptoms on a 10-point scale and using questionnaires completed by patients and doctors. Study Findings: 6084 participants from nine countries joined the study. They were mostly women (78%) with an average age of around 50. Common symptoms included leg pain and leg heaviness. Treatments consisted mainly of drugs active on vein function, like MPFF and diosmin, along with compression stockings and creams. Conservative treatment led to symptom improvement in 89% of patients after 2 weeks and 96% at 4 weeks. Pain and leg heaviness improved in most patients (82% and 71% over the same period) while cramps, and swelling showed improvement in 45.5% and 46% of patients, respectively. Patients reported a significant decrease in symptom intensity, and doctors observed a reduction in disease severity. MPFF was associated with the highest reduction in symptom intensity. Improvements in quality of life were observed with all treatments but were greatest for MPFF. Conclusion: The study highlights that conservative treatments, especially MPFF, are associated with significant improvements in the clinical signs and symptoms of patients with CVD as well as in their quality of life. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
38. Impact of lymphedema in the management of venous leg ulcers.
- Author
-
Moon, Tina, O'Donnell, Thomas F, Weycker, Derek, and Iafrati, Mark
- Subjects
- *
LYMPHEDEMA , *DATABASES , *RETROSPECTIVE studies , *HEALTH insurance reimbursement , *HEALTH insurance , *RESEARCH funding , *STATISTICAL sampling , *LONGITUDINAL method ,LEG ulcers - Abstract
Introduction: Lymphedema (LED) in patients with venous leg ulcers (VLU) [VLU+LED] can impair ulcer healing and predispose to cellulitis. There is little data, however, demonstrating how lymphatic dysfunction may impact the clinical course, treatment, and healthcare expenditures for VLU+LED versus VLU−LED patients. Objective: To determine how lymphatic dysfunction might influence treatment and expenditures among VLU patients in a large deidentified healthcare claims database. Methods: A retrospective cohort design and data from the IBM MarketScan Database (April 2013 to March 2019) were employed. Study population comprised VLU patients, and was stratified into two subgroups: VLU+LED (index date = date of first LED diagnosis) and VLU−LED (index dates randomly assigned to match distribution of index dates for VLU+LED). Within each subgroup, patients with <1 year of healthcare claims information before and after their index dates were excluded. Demographics, comorbidities, procedures/treatments, as well as all-cause post-index medical resource utilization and expenditures ($/patient/year) of the two groups were compared. Stabilized inverse probability treatment weights (IPTWs) were employed to adjust for differences between groups in baseline characteristics. Results: A total of 5466 VLU patients were identified (VLU+LED: N = 299; VLU−LED: N = 5167). Overall ambulatory encounters (AMB ENC) and their components were higher in VLU+LED, which were reflected in increased expenditures for this group (Table 1). Treatment with endovenous ablation (EVA) or stenting for venous hypertension as well as for specific measures for LED were higher in the 1-year post-index period for VLU+LED. The use of LED specific therapy was low for both groups, but a greater percentage of VLU+LED patients received therapy, which was predominantly manual lymphatic drainage (17.4%) rather than pneumatic compression (10.7%). Conclusions: The clinical presence of LED in patients with VLU is a marker for a more complex disease process with more episodes of cellulitis and expenditures, but a surprisingly low specific treatment for LED. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
39. Biomarkers and the post-thrombotic syndrome: A systematic review of biomarkers associated with the occurrence of the post-thrombotic syndrome after lower extremity deep venous thrombosis.
- Author
-
Harbsmeier, Aksel Nathan, Altintas, Izzet, Iversen, Kasper, Andersen, Ove, and Nehlin, Jan O.
- Subjects
- *
BIOMARKERS , *ONLINE information services , *C-reactive protein , *INTERLEUKINS , *MEDICAL information storage & retrieval systems , *SYSTEMATIC reviews , *LEG , *VENOUS thrombosis , *RISK assessment , *ADIPONECTIN , *MEDLINE , *POSTTHROMBOTIC syndrome , *FIBRIN fibrinogen degradation products , *TISSUE plasminogen activator , *DISEASE risk factors , *DISEASE complications - Abstract
Introduction: Post-thrombotic syndrome (PTS) is a frequent chronic complication of deep venous thrombosis (DVT). Biomarkers are potentially valuable clinical tools for handling PTS. The purpose of this review was to examine which biomarkers are associated with the development of PTS in adults with lower extremity DVT. Methods: We performed a systematic review of all English language prospective studies of biomarkers and PTS published in PubMed and EMBASE. Studies were included if diagnosing DVT by diagnostic imaging and assessing PTS by clinical scales, for example, the Villalta scale. Biomarkers of thrombophilia and pathological clot properties were not assessed. Data was reported qualitatively. Results: 15 prospective studies were included. Studies varied widely in study design and methods of data analysis. Forty-six different biomarkers were examined, with seven being measured in two or more studies. The most frequently studied biomarkers were D-dimer, CRP, and IL-6. Associations between PTS and D-dimer were predominantly significant, while results on CRP and IL-6 were inconsistent. ICAM-1 was consistently associated with PTS in all studies and at all timepoints. IL-10 was significantly related to PTS development in the largest study and at all time points. Adiponectin, tPA, HRG and TAFI, MMP-1 and -8, and TIMP-1 and -2 were significantly associated with PTS in single studies. Conclusion: (1) Further research on biomarkers and PTS is clearly warranted. (2) Significant differences in study designs made it difficult to draw reliable conclusions regarding individual biomarkers. We suggest the implementation of a standardized framework for the study of biomarkers and PTS, to make comparison of future studies more feasible. (3) D-dimer, ICAM-1, IL-10, MMP-1 and 8, TIMP-1, TIMP-2, and adiponectin are clinical biomarkers of particular interest to include in future studies of PTS. Large scale systemic quantitative proteomic analyses of DVT patients could help identify novel biomarkers of interest in PTS-patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
40. Development and validation of a graduated compression stockings adherence scale.
- Author
-
Yang, Wen-Tao, Ren, Hua-Liang, Zheng, Kai, Jin, Zhen-Yi, Wen, Jia-Hao, Wang, Sheng-Xing, Zhang, Wang-De, and Li, Chun-Min
- Subjects
- *
EXPERIMENTAL design , *STATISTICAL reliability , *RESEARCH methodology , *RESEARCH methodology evaluation , *COMPRESSION garments , *INTERVIEWING , *DISCRIMINANT analysis , *MULTITRAIT multimethod techniques , *CRONBACH'S alpha , *COMPRESSION therapy , *FACTOR analysis , *DESCRIPTIVE statistics , *QUESTIONNAIRES , *RESEARCH funding , *LITERATURE , *EVALUATION ,RESEARCH evaluation - Abstract
Objective: Compression therapy with the use of graduated compression stockings (GCSs) is a common treatment strategy for chronic venous disease (CVD). However, there is no uniform and objective standard to assess adherence to the use of GCSs. The aim of this study is to develop and validate a GCS Compliance Scale (GCSAS) to fill gaps in internationally recognized comprehensive scales and provide a useful tool for future research. Methods: The items included in the GCSAS were based on a review of the literature and open-ended interviews with experts, who screened the initial items using an item-level content validity index. Then, pilot tests were conducted three times with 50 participants. After exclusion of redundant and cross-loading items by exploratory factor analysis, 290 subjects were recruited to evaluate the reliability and validity of the proposed GCSAS. Analyses included internal consistency, test–retest reliability, split-half reliability, construct validity, criterion validity, convergent validity, and discriminant validity. Results: The final GCSAS consisted of 17 items and 5 dimensions. The results of the exploratory factor analysis indicated that the variances of each factor explained were 22.03%, 14.85%, 14.74%, 14.16%, and 13.35%, and all 5 factors explained 79.13% of the variance among the 17 items. The factor loadings of all items were >0.7. Confirmatory factor analysis indicated that the indices were adequate. A significant positive correlation was found between the GCSAS and the Venous Insufficiency Epidemiological and Economic Study - Quality of Life questionnaire scores (r = 0.76, p < 0.001). The Cronbach's alpha coefficient was 0.90, test–retest reliability was 0.81, and split-half reliability was 0.92. Conclusions: The GCSAS showed good validity and reliability to assess compliance with the use of GCSs among patients with CVD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
41. Rationale and current evidence of aquatic exercise therapy in venous disease: A narrative review.
- Author
-
Bissacco, Daniele, Mosti, Giovanni, D'Oria, Mario, Lomazzi, Chiara, Casana, Renato, Morrison, Nick, and Caggiati, Alberto
- Abstract
Chronic venous disorders (CVD) of the lower limbs can be treated with different strategies. Typically, conservative management is based on compression therapy, anticoagulants and venoactive drugs. Endovenous treatments remain the gold standard to treat saphenous insufficiency, with sclerotherapy and surgery maintaining a role in selected cases. In addition, several 'unconventional' approaches have been proposed to prevent CVD progression and complications, minimize symptoms and improve the quality of life and postoperative outcomes. Among these, balneotherapy and aquatic exercises are proving as valid and effective supporting treatments, as mentioned in a growing number of scientific publications. Moreover, aquatic protocols have been studied for both venous and lymphatic insufficiency. For these reasons, they were mentioned in the last CVD guidelines provided by the European Society for Vascular Surgery. The aim of this narrative review is to overview and summarize current literature evidences on the role and effectiveness of aquatic rehabilitative protocols in CVD, reviewing old and current literature. Furthermore, the physical basis of the effects of water immersion on lower limb venous and tissues modifications are also described. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
42. Ethical Considerations and Adverse Events in Cyanoacrylate Embolization for Non-Saphenous Veins: A Case Report
- Author
-
Insoo Park
- Subjects
chronic venous disease ,instructions for use ,cyanoacrylate embolization ,Diseases of the blood and blood-forming organs ,RC633-647.5 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
The cyanoacrylate embolization (CAE) technique for chronic venous disease treatment is less painful and leads to a faster recovery than conventional endovenous thermal treatment. According to the instructions for use (IFU) of the VenaSeal closure system (Medtronic), a representative CAE product, it has only been approved for treating saphenous veins, not non-saphenous veins. Here, we report a case of ignoring the VenaSeal IFU for treating testicular pain using CAE for non-saphenous veins within the abdominal wall, which is a baseless and non-scientific approach nearing malpractice. Hence, it is imperative for physicians to rigorously adhere to the IFU and abstain from experimenting with new treatment methods solely based on personal experience.
- Published
- 2024
- Full Text
- View/download PDF
43. Monocuspid neovalve for deep venous reflux treatment
- Author
-
Sérgio Silva and Nelson Camacho
- Subjects
neovalve ,chronic venous disease ,deep venous insufficiency ,Medicine ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Published
- 2024
- Full Text
- View/download PDF
44. Miscellaneous venous disorders and lymphedema
- Author
-
Maysen E. Calzon, BS, John Blebea, MD, MBA, and Christopher Pittman, MD, FAVLS, FACR
- Subjects
3D printing ,Chronic venous disease ,Edema ,Pitting ,Venous insufficiency ,Surgery ,RD1-811 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Lower extremity edema is a symptom of chronic venous disease and venous insufficiency. However, clinical evaluations rely on the qualitative evaluation of the pitting depth, which is neither well-defined nor quantitative. We created a novel three-dimensionally printed edema ruler as a quantitative method to measure pitting depth. Twenty-five patients (50 legs) with chronic venous disease were evaluated for ankle edema using the edema ruler. The results demonstrate excellent intraclass correlation for both single (0.944, P < .001) and average (0.971, P < .001) measurements. The edema ruler is a noninvasive, useful, and objective tool for the clinical measurement of lower extremity edema.
- Published
- 2024
- Full Text
- View/download PDF
45. Chronic Venous Disease and Varicose Veins
- Author
-
Debus, E. Sebastian, Grundmann, Reinhart T., Debus, E. Sebastian, and Grundmann, Reinhart T.
- Published
- 2023
- Full Text
- View/download PDF
46. Venous Disease Management in the Limb Salvage Patient: Diagnostics, Compression, and Ablation
- Author
-
Cutler, Bianca, Patel, Nikita, Kiguchi, Misaki, Attinger, Christopher E., editor, and Steinberg, John S., editor
- Published
- 2023
- Full Text
- View/download PDF
47. Key Regulators of Angiogenesis and Inflammation Are Dysregulated in Patients with Varicose Veins
- Author
-
Daniel Zalewski, Paulina Chmiel, Przemysław Kołodziej, Marcin Kocki, Marcin Feldo, Janusz Kocki, and Anna Bogucka-Kocka
- Subjects
angiogenesis ,inflammation ,varicose veins ,chronic venous disease ,gene expression ,plasma proteins ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Varicose veins (VVs) are the most common manifestation of chronic venous disease (CVD) and appear as abnormally enlarged and tortuous superficial veins. VVs result from functional abnormalities in the venous circulation of the lower extremities, such as venous hypertension, venous valve incompetence, and venous reflux. Previous studies indicate that enhanced angiogenesis and inflammation contribute to the progression and onset of VVs; however, dysregulations in signaling pathways associated with these processes in VVs patients are poorly understood. Therefore, in our study, we aimed to identify key regulators of angiogenesis and inflammation that are dysregulated in patients with VVs. Expression levels of 18 genes were analyzed in peripheral blood mononuclear cells (PBMC) using real-time PCR, as well as plasma levels of 6 proteins were investigated using ELISA. Higher levels of CCL5, PDGFA, VEGFC, TGF-alpha, TGF-beta 1, and VEGF-A, as well as lower levels of VEGFB and VEGF-C, were found to be statistically significant in the VV group compared to the control subjects without VVs. None of the analyzed factors was associated with the venous localization of the varicosities. The presented study identified dysregulations in key angiogenesis- and inflammation-related factors in PBMC and plasma from VVs patients, providing new insight into molecular mechanisms that could contribute to the development of VVs and point out promising candidates for circulatory biomarkers of this disease.
- Published
- 2024
- Full Text
- View/download PDF
48. The Other Side of Chronic Venous Disorder: Gaining Insights from Patients’ Questions and Perspectives
- Author
-
Daniele Bissacco and Chiara Pisani
- Subjects
chronic venous disease ,CEAP ,great saphenous vein ,varicose veins ,Medicine - Abstract
Venous disorders encompass a diverse range of manifestations and diseases, impacting a significant portion of the population. While life-threatening conditions are uncommon in non-thrombotic disorders, like telangiectasias or uncomplicated varicose veins (VVs), these conditions still have a substantial impact on affected individuals. Ensuring that patients are well informed about their venous disorder is a crucial step in their treatment journey. Providing them with valuable information regarding the disease’s natural progression and available therapeutic options plays a pivotal role in optimizing their care. When patients are diagnosed with venous disorders, they often have numerous questions and concerns they want to discuss with their healthcare providers. Addressing these inquiries not only improves patients’ knowledge and understanding but also influences their treatment compliance and overall outcomes. Therefore, it is of utmost importance to provide comprehensive explanations that address any doubts, uncertainties, and areas of confusion that patients may have. This report aims to present a concise, practical, and informative guide to venous disorders, focusing specifically on the common questions frequently raised by patients in everyday clinical practice. By serving as a valuable resource for healthcare professionals working in the field of venous diseases, this guide equips them with the necessary tools to effectively address patients’ concerns and provide optimal care. By bridging the gap between patients’ inquiries and medical expertise, this guide strives to enhance therapeutic outcomes and improve the overall management of venous disorders, ultimately empowering patients in their treatment journey.
- Published
- 2024
- Full Text
- View/download PDF
49. Letter to the Editor Regarding “Cardiovascular Insights for the Appropriate Management of Chronic Venous Disease: A Narrative Review of Implications for the Use of Venoactive Drugs”
- Author
-
Poggialini, Mauro and Travagli, Valter
- Published
- 2024
- Full Text
- View/download PDF
50. A Response to: Letter to the Editor Regarding “Cardiovascular Insights for the Appropriate Management of Chronic Venous Disease: A Narrative Review of Implications for the Use of Venoactive Drugs”
- Author
-
Gianesini, Sergio
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.